Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Japanese CML treatment patterns revealed in large database study

NCT ID NCT07150793

Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at how 754 people with chronic myeloid leukemia (CML) in Japan were treated with drugs called tyrosine kinase inhibitors (TKIs) between 2011 and 2019. Researchers used a hospital database to track which TKIs patients received, how often they switched or stopped treatment, and the costs involved. The goal was to describe real-world treatment patterns, not to test a new therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

754 people

The number who actually took part.

Started

Jul 2022

Finished

Feb 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This was a retrospective, non-interventional cohort study.

Ages

15 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Patients who met all the below inclusion criteria and none of the exclusion criteria were included in the study. Inclusion criteria: * Patients who had at least one TKI prescription during the selection period, * a confirmed diagnosis of chronic phase CML recorded before or at the index date, * were aged 15 years or older at the index date, and * had at least 12-months continuous pre-index period. Exclusion criteria: * Patients who had at least one TKI prescription in the 12 months preceding the index date (washout period to catch the 1st line of treatment \[LoT\]), * a confirmed diagnosis of CML blast crisis or accelerated phase recorded prior to, at, or within 6 months after the index date, * a confirmed diagnosis of acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) within 6 months after the index date, * a medical record of chemotherapy (not including hydroxyurea) within 6 months after the index date, * a stem cell transplant procedure recorded during the pre-index period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myeloid leukemia, chronic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myelogenous, Chronic, BCR-ABL Positive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myeloid leukemia, chronic

Contacts and locations

Locations

  • Novartis

    East Hanover, New Jersey, 07936, United States